Celcuity (CELC) Stock Price & Analysis
Score
AI Analysis
SnapshotCelcuity is a growth-led story right now — Growth 100/100 is the pillar doing the heavy lifting (overall 68/100) in Biotechnology. In Biotechnology, that score mix is usable but not one-dimensional. Street targets still imply ~146% upside.
Price History
Price: —
Fair value: —
—
P/E (TTM): —
Net Income (TTM): —
Score: —
—
Score Breakdown
Market percentile scores loading…
Value
Growth
Quality
Financial Summary
Celcuity Inc. (CELC) last printed $64.37. Equity value is $3.15B. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
About
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.